Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

791
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
791
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

932
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
932
Cross-bridge Cycle01:26

Cross-bridge Cycle

117.4K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.4K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Muscle Contraction01:10

Muscle Contraction

6.4K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A case of neuronal intranuclear inclusion disease diagnosed 19 years after onset through clinical re-evaluation].

Rinsho shinkeigaku = Clinical neurology·2025
Same author

Immunological and therapeutic insights in autoimmune autonomic ganglionopathy: What is the position of apheresis in immunotherapy?

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2024
Same author

The Presence of Ganglionic Acetylcholine Receptor Antibodies in Sera from Patients with Functional Gastrointestinal Disorders: A Preliminary Study.

Journal of personalized medicine·2024
Same author

Evaluation of cell adhesion molecules (LFA-1 and L-selectin) in ankylosing spondylitis patients after treatment with β-D-mannuronic acid (M2000).

The Indian journal of medical research·2023
Same author

Immunotherapy for ocular myasthenia gravis: an observational study in Japan.

Therapeutic advances in neurological disorders·2023
Same author

Effectiveness of treatment for 31 patients with seropositive autoimmune autonomic ganglionopathy in Japan.

Therapeutic advances in neurological disorders·2022

Related Experiment Video

Updated: Jun 26, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K

[Lambert-Eaton Myasthenic Syndrome].

Hidenori Matsuo1

  • 1Department of Neurology, National Hospital Organization Nagasaki National Hospital.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 14, 2024
PubMed
Summary

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder causing muscle weakness due to antibodies against voltage-gated calcium channels. Diagnosis involves electrophysiology and antibody testing, with treatments including tumor therapy and 3,4-diaminopyridine.

Area of Science:

  • Neurology
  • Immunology
  • Oncology

Background:

  • Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder affecting neuromuscular junctions.
  • It presents with proximal muscle weakness, reduced reflexes, and autonomic dysfunction.
  • Prevalence is approximately 0.25-0.27 per 100,000 population.

Purpose of the Study:

  • To summarize diagnostic criteria and treatment strategies for Lambert-Eaton myasthenic syndrome.
  • To highlight the association between LEMS and small-cell lung carcinoma (SCLC).
  • To provide an overview of current clinical practice guidelines for LEMS management.

Main Methods:

  • Review of diagnostic criteria, including Japanese LEMS diagnostic criteria 2022.
  • Analysis of pathogenic autoantibodies, particularly P/Q-type voltage-gated calcium channel (VGCC) antibodies.

More Related Videos

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

31.8K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.6K

Related Experiment Videos

Last Updated: Jun 26, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

31.8K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.6K
  • Examination of treatment modalities: oncological, immunotherapeutic, and symptomatic.

    • Main Results:

    • Muscle weakness in LEMS is caused by autoantibodies against presynaptic VGCCs.
    • A significant percentage (50-60%) of LEMS patients have an associated SCLC.
    • P/Q-type VGCC antibody positivity is a strong diagnostic indicator.
    • 3,4-diaminopyridine is effective for symptomatic treatment in most patients.

    Conclusions:

    • Accurate LEMS diagnosis relies on electrophysiological findings and myasthenic symptoms.
    • Effective tumor treatment can improve LEMS symptoms in SCLC patients.
    • Established treatment algorithms guide LEMS management, incorporating oncological, immunotherapeutic, and symptomatic approaches.